Vera Therapeutics Inc. (VERA) Commences $75M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St set to open higher as chips recover, megacap earnings loom
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall St set to open higher as chips recover, megacap earnings loom
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threatÂ
- AMC Entertainment posts record quarterly revenue and EBITDA in Q2 2026
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
February 1, 2023 4:01 PM ESTBRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Vera), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced a public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its Class A common stock. All of the shares are being offered by Vera.
In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public... More
